PMID- 35116804
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220205
IS  - 2219-6803 (Electronic)
IS  - 2218-676X (Print)
IS  - 2218-676X (Linking)
VI  - 8
IP  - 2
DP  - 2019 Apr
TI  - Effectiveness of crizotinib in a patient with mesenchymal-epithelial transition 
      overexpression/fluorescence in situ hybridization-negative/next-generation 
      sequencing-negative advanced lung adenocarcinoma: a case report.
PG  - 705-708
LID - 10.21037/tcr.2019.03.14 [doi]
AB  - Crizotinib, an oral ATP-competitive tyrosine kinase inhibitor (TKI), has shown 
      significant activity against advanced non-small cell lung cancer (NSCLC) tumors 
      harboring mesenchymal-epithelial transition (MET) amplification or exon 14 
      mutation. Methods to detect MET alteration includes immunohistochemistry (IHC), 
      fluorescence in situ hybridization (FISH), next-generation sequencing (NGS) and 
      reverse transcription polymerase chain reaction (RT-PCR). Despite multiple 
      methods for detecting MET alteration, the response to crizotinib in advanced 
      NSCLC patients according to the results of MET IHC staining is still unknown. 
      This case showed effectiveness of crizotinib in a pretreated patient with 
      advanced lung adenocarcinoma detected as MET 
      overexpression/FISH-negative/NGS-negative. MET overexpression might be a 
      biomarker for predicting efficacy of crizotinib.
CI  - 2019 Translational Cancer Research. All rights reserved.
FAU - Song, Peng
AU  - Song P
AD  - Department of Thoracic Surgery, National Cancer Center/National Clinical Research 
      Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking 
      Union Medical College, Beijing 100021, China.
FAU - Liu, Li
AU  - Liu L
AD  - Department of Pathology, National Cancer Center/National Clinical Research Center 
      for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union 
      Medical College, Beijing 100021, China.
FAU - Liu, Yutao
AU  - Liu Y
AD  - Department of Medical Oncology, National Cancer Center/National Clinical Research 
      Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking 
      Union Medical College, Beijing 100021, China.
FAU - Zhang, Tao
AU  - Zhang T
AD  - Department of Radiation Oncology, National Cancer Center/National Clinical 
      Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences 
      and Peking Union Medical College, Beijing 100021, China.
FAU - Guo, Lei
AU  - Guo L
AD  - Department of Pathology, National Cancer Center/National Clinical Research Center 
      for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union 
      Medical College, Beijing 100021, China.
FAU - Li, Weihua
AU  - Li W
AD  - Department of Pathology, National Cancer Center/National Clinical Research Center 
      for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union 
      Medical College, Beijing 100021, China.
FAU - Ying, Jianming
AU  - Ying J
AD  - Department of Pathology, National Cancer Center/National Clinical Research Center 
      for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union 
      Medical College, Beijing 100021, China.
FAU - Yang, Lin
AU  - Yang L
AD  - Department of Pathology, National Cancer Center/National Clinical Research Center 
      for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union 
      Medical College, Beijing 100021, China.
FAU - Gao, Shugeng
AU  - Gao S
AD  - Department of Thoracic Surgery, National Cancer Center/National Clinical Research 
      Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking 
      Union Medical College, Beijing 100021, China.
LA  - eng
PT  - Case Reports
PL  - China
TA  - Transl Cancer Res
JT  - Translational cancer research
JID - 101585958
PMC - PMC8798553
OTO - NOTNLM
OT  - Lung adenocarcinoma
OT  - crizotinib
OT  - fluorescence in situ hybridization (FISH)
OT  - immunohistochemistry (IHC)
OT  - next-generation sequencing (NGS)
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure 
      form (available at http://dx.doi.org/10.21037/tcr.2019.03.14). The authors have 
      no conflicts of interest to declare.
EDAT- 2019/04/01 00:00
MHDA- 2019/04/01 00:01
PMCR- 2019/04/01
CRDT- 2022/02/04 05:49
PHST- 2018/11/29 00:00 [received]
PHST- 2019/03/08 00:00 [accepted]
PHST- 2022/02/04 05:49 [entrez]
PHST- 2019/04/01 00:00 [pubmed]
PHST- 2019/04/01 00:01 [medline]
PHST- 2019/04/01 00:00 [pmc-release]
AID - tcr-08-02-705 [pii]
AID - 10.21037/tcr.2019.03.14 [doi]
PST - ppublish
SO  - Transl Cancer Res. 2019 Apr;8(2):705-708. doi: 10.21037/tcr.2019.03.14.